Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes.
Criteria, scoring systems, and treatment algorithms for myelodysplastic syndromes (MDS) have been updated repeatedly in recent years. This apparently results from increased awareness and early recognition of the disease, an increasing number of new diagnostic and prognostic markers and tools, and new therapeutic options that may change the course and thus prognosis in MDS. To address these challenges and to create useful new diagnostic and prognostic parameters and scores, the German-Austrian Working Group for Studying Prognostic Factors in MDS was established in 2003 and later was extended to centers in Switzerland (D-A-CH group). In addition, the group cooperates with the European LeukemiaNet, the MDS Foundation, and other national and international working groups in order to improve diagnosis and prognostication. The current article represents a meeting report from the latest workshop organized by the group in Vienna in October 2008.
Valent
Peter
P
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria. peter.valent@meduniwien.ac.at
Hofmann
Wolf-Karsten
WK
Büsche
Guntram
G
Sotlar
Karl
K
Horny
Hans-Peter
HP
Haase
Detlef
D
Haferlach
Torsten
T
Kern
Wolfgang
W
Bettelheim
Peter
P
Baumgartner
Christian
C
Sperr
Wolfgang R
WR
Nösslinger
Thomas
T
Wimazal
Friedrich
F
Giagounidis
Aristoteles A
AA
Lübbert
Michael
M
Krieger
Otto
O
Kolb
Hans-Jochem
HJ
Stauder
Reinhard
R
Pfeilstöcker
Michael
M
Gattermann
Norbert
N
Fonatsch
Christa
C
Aul
Carlo
C
Germing
Ulrich
U
D001317:Austria; D015415:Biomarkers; D020732:Cytogenetic Analysis; D019937:Diagnostic Techniques and Procedures; D005434:Flow Cytometry; D005858:Germany; D006801:Humans; D007150:Immunohistochemistry; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000175:diagnosis*; D011379:Prognosis; D013557:Switzerland
D015415:Biomarkers